Xlife Sciences AG (SWX:XLS)

Market Cap	130.34M
Revenue (ttm)	990.27K
Net Income (ttm)	21.24M
Shares Out	5.74M
EPS (ttm)	2.61
PE Ratio	8.70
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,396
Average Volume	3,543
Open	23.50
Previous Close	23.50
Day's Range	21.10 - 24.00
52-Week Range	16.55 - 45.00
Beta	0.39
RSI	57.68
Earnings Date	Apr 25, 2025

About Xlife Sciences AG

Xlife Sciences AG focuses on the development and commercialization of technologies in the life sciences sector. The company’s project consists of technology platforms that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data. It also engages in developing mono-and bispecific anti-tumor antibodies for the treatment of life-threatening diseases; researching, developing, and manufacturing chemical and active pharmaceutical ingredients for human and veterinary medicines; and early identifi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 17
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: XLS

Financial Performance

In 2023, Xlife Sciences AG's revenue was 988,435, a decrease of -3.85% compared to the previous year's 1.03 million. Earnings were 14.88 million, an increase of 3.96%.